Skip to main content
Erschienen in: European Journal of Epidemiology 2/2019

08.12.2018 | SCREENING

Contribution of the OC Sensor® immunoassay in comparison to the Hemoccult II® guaiac-test in organized colorectal cancer screening

verfasst von: Carole Vitellius, Margot Laly, Anne-Sophie Banaszuk, Isabelle Deherce, Nathanaëlle Cornet, Sandrine Bertrais, Patrick Saulnier, François-Xavier Caroli-Bosc

Erschienen in: European Journal of Epidemiology | Ausgabe 2/2019

Einloggen, um Zugang zu erhalten

Abstract

Colorectal cancer (CRC) is a major cause of cancer-related death of worldwide with high incidence and mortality rate, accessible to a screening program in France, first with guaiac- based fecal occult blood test (g-FOBT) then with fecal immunochemical tests (FIT), since 2015, because of better accuracy. The aim of our study was to compare the characteristics of screen-detected lesions in two successive CRC screening campaigns, using two different tests (Hemoccult II® and OC Sensor®) in the department of Maine-et-Loire, and to precise the performance of these tests [participation rate, detection rates (DR), positive predictive value (PPV)]. Participants, invited by CAP SANTE 49, with polyps or cancer at the colonoscopy after a positive screening test between 01/01/2013 and 31/12/2016 were included. A guaiac-based fecal occult blood test (g-FOBT) was used from January 2013 to December 2014 and a FIT was used from June 2015 to December 2016). 2575 participants, 642 in g-FOBT group and 1933 in FIT group had lesions. Participation rate was not different between tests (p = 0.104), whereas DR and PPV were statistically higher in FIT for all lesions (2.61, 95% CI [2.50–2.70] vs 0.93, 95% CI [0.90–1.00], p < 0.0001 and 64.84, 95% CI [63.10–66.60], 50.00, 95% CI [47.30–52.70], p < 0.0001 respectively). FIT detects more precancerous lesions (adenomas, p < 0.001, and advanced adenomas, p < 0.001) than g-FOBT but g-FOBT detects more serrated polyps (p = 0.025). AAs were more in right colon in FIT than g-FOBT (p = 0.035). No different participation rate was detected between FIT and g-FOBT but DR and PPV of all lesions was higher with FIT.
Literatur
2.
Zurück zum Zitat Holleczek B, Rossi S, Domenic A, Innos K, Minicozzi P, Francisci S, et al. On-going improvement and persistent differences in the survival for patients with colon and rectum cancer across Europe 1999–2007—results from the EUROCARE-5 study. Eur J Cancer. 1990;2015(51):2158–68. Holleczek B, Rossi S, Domenic A, Innos K, Minicozzi P, Francisci S, et al. On-going improvement and persistent differences in the survival for patients with colon and rectum cancer across Europe 1999–2007—results from the EUROCARE-5 study. Eur J Cancer. 1990;2015(51):2158–68.
4.
Zurück zum Zitat Selby JV. Effect of fecal occult blood testing on mortality from colorectal cancer: a case–control study. Ann Intern Med. 1993;118:1.CrossRefPubMed Selby JV. Effect of fecal occult blood testing on mortality from colorectal cancer: a case–control study. Ann Intern Med. 1993;118:1.CrossRefPubMed
5.
Zurück zum Zitat Hardcastle JD, Chamberlain JO, Robinson MH, Moss SM, Amar SS, Balfour TW, et al. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet. 1996;348:1472–7.CrossRefPubMed Hardcastle JD, Chamberlain JO, Robinson MH, Moss SM, Amar SS, Balfour TW, et al. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet. 1996;348:1472–7.CrossRefPubMed
6.
Zurück zum Zitat Kronborg O, Fenger C, Olsen J, Jørgensen OD, Søndergaard O. Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet. 1996;348:1467–71.CrossRefPubMed Kronborg O, Fenger C, Olsen J, Jørgensen OD, Søndergaard O. Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet. 1996;348:1467–71.CrossRefPubMed
7.
Zurück zum Zitat Faivre J, Dancourt V, Lejeune C, Tazi MA, Lamour J, Gerard D, et al. Reduction in colorectal cancer mortality by fecal occult blood screening in a French controlled study. Gastroenterology. 2004;126:1674–80.CrossRefPubMed Faivre J, Dancourt V, Lejeune C, Tazi MA, Lamour J, Gerard D, et al. Reduction in colorectal cancer mortality by fecal occult blood screening in a French controlled study. Gastroenterology. 2004;126:1674–80.CrossRefPubMed
8.
Zurück zum Zitat Mandel JS, Bond JH, Church TR, Snover DC, Bradley GM, Schuman LM, et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. N Engl J Med. 1993;328:1365–71.CrossRefPubMed Mandel JS, Bond JH, Church TR, Snover DC, Bradley GM, Schuman LM, et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. N Engl J Med. 1993;328:1365–71.CrossRefPubMed
9.
Zurück zum Zitat Tinmouth J, Lansdorp-Vogelaar I, Allison JE. Faecal immunochemical tests versus guaiac faecal occult blood tests: what clinicians and colorectal cancer screening programme organisers need to know. Gut. 2015;64:1327–37.CrossRefPubMed Tinmouth J, Lansdorp-Vogelaar I, Allison JE. Faecal immunochemical tests versus guaiac faecal occult blood tests: what clinicians and colorectal cancer screening programme organisers need to know. Gut. 2015;64:1327–37.CrossRefPubMed
10.
Zurück zum Zitat Chiu H-M, Chen SL-S, Yen AM-F, Chiu SY-H, Fann JC-Y, Lee Y-C, et al. Effectiveness of fecal immunochemical testing in reducing colorectal cancer mortality from the One Million Taiwanese Screening Program. Cancer. 2015;121:3221–9.CrossRefPubMed Chiu H-M, Chen SL-S, Yen AM-F, Chiu SY-H, Fann JC-Y, Lee Y-C, et al. Effectiveness of fecal immunochemical testing in reducing colorectal cancer mortality from the One Million Taiwanese Screening Program. Cancer. 2015;121:3221–9.CrossRefPubMed
11.
Zurück zum Zitat Zorzi M, Fedeli U, Schievano E, Bovo E, Guzzinati S, Baracco S, et al. Impact on colorectal cancer mortality of screening programmes based on the faecal immunochemical test. Gut. 2015;64:784–90.CrossRefPubMed Zorzi M, Fedeli U, Schievano E, Bovo E, Guzzinati S, Baracco S, et al. Impact on colorectal cancer mortality of screening programmes based on the faecal immunochemical test. Gut. 2015;64:784–90.CrossRefPubMed
12.
Zurück zum Zitat Lee JK, Liles EG, Bent S, Levin TR, Corley DA. Accuracy of fecal immunochemical tests for colorectal cancer: systematic review and meta-analysis. Ann Intern Med. 2014;160:171.CrossRefPubMedPubMedCentral Lee JK, Liles EG, Bent S, Levin TR, Corley DA. Accuracy of fecal immunochemical tests for colorectal cancer: systematic review and meta-analysis. Ann Intern Med. 2014;160:171.CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Guittet L, Bouvier V, Mariotte N, Vallee JP, Levillain R, Tichet J, et al. Comparison of a guaiac and an immunochemical faecal occult blood test for the detection of colonic lesions according to lesion type and location. Br J Cancer. 2009;100:1230–5.CrossRefPubMedPubMedCentral Guittet L, Bouvier V, Mariotte N, Vallee JP, Levillain R, Tichet J, et al. Comparison of a guaiac and an immunochemical faecal occult blood test for the detection of colonic lesions according to lesion type and location. Br J Cancer. 2009;100:1230–5.CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Chaptini L, Chaaya A, Depalma F, Hunter K, Peikin S, Laine L. Variation in polyp size estimation among endoscopists and impact on surveillance intervals. Gastrointest Endosc. 2014;80:652–9.CrossRefPubMed Chaptini L, Chaaya A, Depalma F, Hunter K, Peikin S, Laine L. Variation in polyp size estimation among endoscopists and impact on surveillance intervals. Gastrointest Endosc. 2014;80:652–9.CrossRefPubMed
16.
Zurück zum Zitat Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010;17:1471–4.CrossRefPubMed Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010;17:1471–4.CrossRefPubMed
17.
Zurück zum Zitat Winawer SJ, Zauber AG, Fletcher RH, Stillman JS, O’Brien MJ, Levin B, et al. Guidelines for colonoscopy surveillance after polypectomy: a consensus update by the US Multi-Society Task Force on colorectal cancer and the American Cancer Society. Gastroenterology. 2006;130:1872–85.CrossRefPubMed Winawer SJ, Zauber AG, Fletcher RH, Stillman JS, O’Brien MJ, Levin B, et al. Guidelines for colonoscopy surveillance after polypectomy: a consensus update by the US Multi-Society Task Force on colorectal cancer and the American Cancer Society. Gastroenterology. 2006;130:1872–85.CrossRefPubMed
18.
Zurück zum Zitat Rosman AS, Korsten MA. Effect of verification bias on the sensitivity of fecal occult blood testing: a meta-analysis. J Gen Intern Med. 2010;25:1211–21.CrossRefPubMedPubMedCentral Rosman AS, Korsten MA. Effect of verification bias on the sensitivity of fecal occult blood testing: a meta-analysis. J Gen Intern Med. 2010;25:1211–21.CrossRefPubMedPubMedCentral
19.
Zurück zum Zitat Launois R, Le Moine J-G, Uzzan B, Fiestas Navarrete LI, Benamouzig R. Systematic review and bivariate/HSROC random-effect meta-analysis of immunochemical and guaiac-based fecal occult blood tests for colorectal cancer screening. Eur J Gastroenterol Hepatol. 2014;26:978–89.CrossRefPubMed Launois R, Le Moine J-G, Uzzan B, Fiestas Navarrete LI, Benamouzig R. Systematic review and bivariate/HSROC random-effect meta-analysis of immunochemical and guaiac-based fecal occult blood tests for colorectal cancer screening. Eur J Gastroenterol Hepatol. 2014;26:978–89.CrossRefPubMed
21.
Zurück zum Zitat van Rossum LG, van Rijn AF, Laheij RJ, van Oijen MG, Fockens P, van Krieken HH, et al. Random comparison of guaiac and immunochemical fecal occult blood tests for colorectal cancer in a screening population. Gastroenterology. 2008;135:82–90.CrossRefPubMed van Rossum LG, van Rijn AF, Laheij RJ, van Oijen MG, Fockens P, van Krieken HH, et al. Random comparison of guaiac and immunochemical fecal occult blood tests for colorectal cancer in a screening population. Gastroenterology. 2008;135:82–90.CrossRefPubMed
22.
Zurück zum Zitat Federici A, Giorgi Rossi P, Borgia P, Bartolozzi F, Farchi S, Gausticchi G. The immunochemical faecal occult blood test leads to higher compliance than the guaiac for colorectal cancer screening programmes: a cluster randomized controlled trial. J Med Screen. 2005;12:83–8.CrossRefPubMed Federici A, Giorgi Rossi P, Borgia P, Bartolozzi F, Farchi S, Gausticchi G. The immunochemical faecal occult blood test leads to higher compliance than the guaiac for colorectal cancer screening programmes: a cluster randomized controlled trial. J Med Screen. 2005;12:83–8.CrossRefPubMed
23.
Zurück zum Zitat Piette C, Durand G, Bretagne J-F, Faivre J. Additional mailing phase for FIT after a medical offer phase: the best way to improve compliance with colorectal cancer screening in France. Dig Liver Dis. 2017;49:308–11.CrossRefPubMed Piette C, Durand G, Bretagne J-F, Faivre J. Additional mailing phase for FIT after a medical offer phase: the best way to improve compliance with colorectal cancer screening in France. Dig Liver Dis. 2017;49:308–11.CrossRefPubMed
24.
Zurück zum Zitat Ko CW, Dominitz JA, Nguyen TD. Fecal occult blood testing in a general medical clinic: comparison between guaiac-based and immunochemical-based tests. Am J Med. 2003;115:111–4.CrossRefPubMed Ko CW, Dominitz JA, Nguyen TD. Fecal occult blood testing in a general medical clinic: comparison between guaiac-based and immunochemical-based tests. Am J Med. 2003;115:111–4.CrossRefPubMed
25.
Zurück zum Zitat Corley DA, Jensen CD, Quinn VP, Doubeni CA, Zauber AG, Lee JK, et al. Association between time to colonoscopy after a positive fecal test result and risk of colorectal cancer and cancer stage at diagnosis. JAMA. 2017;317:1631–41.CrossRefPubMedPubMedCentral Corley DA, Jensen CD, Quinn VP, Doubeni CA, Zauber AG, Lee JK, et al. Association between time to colonoscopy after a positive fecal test result and risk of colorectal cancer and cancer stage at diagnosis. JAMA. 2017;317:1631–41.CrossRefPubMedPubMedCentral
26.
Zurück zum Zitat Allison JE, Tekawa IS, Ransom LJ, Adrain AL. A comparison of fecal occult-blood tests for colorectal-cancer screening. N Engl J Med. 1996;334:155–9.CrossRefPubMed Allison JE, Tekawa IS, Ransom LJ, Adrain AL. A comparison of fecal occult-blood tests for colorectal-cancer screening. N Engl J Med. 1996;334:155–9.CrossRefPubMed
27.
Zurück zum Zitat de Wijkerslooth TR, Stoop EM, Bossuyt PM, Meijer GA, van Ballegooijen M, van Roon AHC, et al. Immunochemical fecal occult blood testing is equally sensitive for proximal and distal advanced neoplasia. Am J Gastroenterol. 2012;107:1570–8.CrossRefPubMed de Wijkerslooth TR, Stoop EM, Bossuyt PM, Meijer GA, van Ballegooijen M, van Roon AHC, et al. Immunochemical fecal occult blood testing is equally sensitive for proximal and distal advanced neoplasia. Am J Gastroenterol. 2012;107:1570–8.CrossRefPubMed
28.
Zurück zum Zitat Castiglione G, Zappa M, Grazzini G, Mazzotta A, Biagini M, Salvadori P, et al. Immunochemical vs guaiac faecal occult blood tests in a population-based screening programme for colorectal cancer. Br J Cancer. 1996;74:141–4.CrossRefPubMedPubMedCentral Castiglione G, Zappa M, Grazzini G, Mazzotta A, Biagini M, Salvadori P, et al. Immunochemical vs guaiac faecal occult blood tests in a population-based screening programme for colorectal cancer. Br J Cancer. 1996;74:141–4.CrossRefPubMedPubMedCentral
29.
Zurück zum Zitat Guittet L, Bouvier V, Mariotte N, Vallee JP, Arsène D, Boutreux S, et al. Comparison of a guaiac based and an immunochemical faecal occult blood test in screening for colorectal cancer in a general average risk population. Gut. 2007;56:210–4.CrossRefPubMed Guittet L, Bouvier V, Mariotte N, Vallee JP, Arsène D, Boutreux S, et al. Comparison of a guaiac based and an immunochemical faecal occult blood test in screening for colorectal cancer in a general average risk population. Gut. 2007;56:210–4.CrossRefPubMed
30.
Zurück zum Zitat Levi Z, Birkenfeld S, Vilkin A, Bar-Chana M, Lifshitz I, Chared M, et al. A higher detection rate for colorectal cancer and advanced adenomatous polyp for screening with immunochemical fecal occult blood test than guaiac fecal occult blood test, despite lower compliance rate. A prospective, controlled, feasibility study. Int J Cancer. 2011;128:2415–24.CrossRefPubMed Levi Z, Birkenfeld S, Vilkin A, Bar-Chana M, Lifshitz I, Chared M, et al. A higher detection rate for colorectal cancer and advanced adenomatous polyp for screening with immunochemical fecal occult blood test than guaiac fecal occult blood test, despite lower compliance rate. A prospective, controlled, feasibility study. Int J Cancer. 2011;128:2415–24.CrossRefPubMed
31.
Zurück zum Zitat Nakama H, Kamijo N, Abdul Fattah AS, Zhang B. Validity of immunological faecal occult blood screening for colorectal cancer: a follow up study. J Med Screen. 1996;3:63–5.CrossRefPubMed Nakama H, Kamijo N, Abdul Fattah AS, Zhang B. Validity of immunological faecal occult blood screening for colorectal cancer: a follow up study. J Med Screen. 1996;3:63–5.CrossRefPubMed
32.
Zurück zum Zitat Robinson MH, Marks CG, Farrands PA, Thomas WM, Hardcastle JD. Population screening for colorectal cancer: comparison between guaiac and immunological faecal occult blood tests. Br J Surg. 1994;81:448–51.CrossRefPubMed Robinson MH, Marks CG, Farrands PA, Thomas WM, Hardcastle JD. Population screening for colorectal cancer: comparison between guaiac and immunological faecal occult blood tests. Br J Surg. 1994;81:448–51.CrossRefPubMed
33.
Zurück zum Zitat Petrelli N, Michalek AM, Freedman A, Baroni M, Mink I, Rodriguez-Bigas M. Immunochemical versus guaiac occult blood stool tests: results of a community-based screening program. Surg Oncol. 1994;3:27–36.CrossRefPubMed Petrelli N, Michalek AM, Freedman A, Baroni M, Mink I, Rodriguez-Bigas M. Immunochemical versus guaiac occult blood stool tests: results of a community-based screening program. Surg Oncol. 1994;3:27–36.CrossRefPubMed
34.
Zurück zum Zitat Haug U, Knudsen AB, Brenner H, Kuntz KM. Is fecal occult blood testing more sensitive for left- versus right-sided colorectal neoplasia? A systematic literature review. Expert Rev Mol Diagn. 2011;11:605–16.CrossRefPubMed Haug U, Knudsen AB, Brenner H, Kuntz KM. Is fecal occult blood testing more sensitive for left- versus right-sided colorectal neoplasia? A systematic literature review. Expert Rev Mol Diagn. 2011;11:605–16.CrossRefPubMed
35.
Zurück zum Zitat Hirai HW, Tsoi KKF, Chan JYC, Wong SH, Ching JYL, Wong MCS, et al. Systematic review with meta-analysis: faecal occult blood tests show lower colorectal cancer detection rates in the proximal colon in colonoscopy-verified diagnostic studies. Aliment Pharmacol Ther. 2016;43:755–64.CrossRefPubMed Hirai HW, Tsoi KKF, Chan JYC, Wong SH, Ching JYL, Wong MCS, et al. Systematic review with meta-analysis: faecal occult blood tests show lower colorectal cancer detection rates in the proximal colon in colonoscopy-verified diagnostic studies. Aliment Pharmacol Ther. 2016;43:755–64.CrossRefPubMed
36.
Zurück zum Zitat Graser A, Stieber P, Nagel D, Schäfer C, Horst D, Becker CR, et al. Comparison of CT colonography, colonoscopy, sigmoidoscopy and faecal occult blood tests for the detection of advanced adenoma in an average risk population. Gut. 2009;58:241–8.CrossRefPubMed Graser A, Stieber P, Nagel D, Schäfer C, Horst D, Becker CR, et al. Comparison of CT colonography, colonoscopy, sigmoidoscopy and faecal occult blood tests for the detection of advanced adenoma in an average risk population. Gut. 2009;58:241–8.CrossRefPubMed
37.
Zurück zum Zitat Jouve JL, Remontet L, Dancourt V, Lejeune C, Benhamiche AM, Faivre J, et al. Estimation of screening test (Hemoccult) sensitivity in colorectal cancer mass screening. Br J Cancer. 2001;84:1477–81.CrossRefPubMedPubMedCentral Jouve JL, Remontet L, Dancourt V, Lejeune C, Benhamiche AM, Faivre J, et al. Estimation of screening test (Hemoccult) sensitivity in colorectal cancer mass screening. Br J Cancer. 2001;84:1477–81.CrossRefPubMedPubMedCentral
38.
Zurück zum Zitat Portillo I, Arana-Arri E, Idigoras I, Bilbao I, Martínez-Indart L, Bujanda L, et al. Colorectal and interval cancers of the Colorectal Cancer Screening Program in the Basque Country (Spain). World J Gastroenterol. 2017;23:2731–42.CrossRefPubMedPubMedCentral Portillo I, Arana-Arri E, Idigoras I, Bilbao I, Martínez-Indart L, Bujanda L, et al. Colorectal and interval cancers of the Colorectal Cancer Screening Program in the Basque Country (Spain). World J Gastroenterol. 2017;23:2731–42.CrossRefPubMedPubMedCentral
39.
Zurück zum Zitat Abdeljawad K, Vemulapalli KC, Kahi CJ, Cummings OW, Snover DC, Rex DK. Sessile serrated polyp prevalence determined by a colonoscopist with a high lesion detection rate and an experienced pathologist. Gastrointest Endosc. 2015;81:517–24.CrossRefPubMed Abdeljawad K, Vemulapalli KC, Kahi CJ, Cummings OW, Snover DC, Rex DK. Sessile serrated polyp prevalence determined by a colonoscopist with a high lesion detection rate and an experienced pathologist. Gastrointest Endosc. 2015;81:517–24.CrossRefPubMed
40.
Zurück zum Zitat East JE, Atkin WS, Bateman AC, Clark SK, Dolwani S, Ket SN, et al. British Society of Gastroenterology position statement on serrated polyps in the colon and rectum. Gut. 2017;66:1181–96.CrossRefPubMed East JE, Atkin WS, Bateman AC, Clark SK, Dolwani S, Ket SN, et al. British Society of Gastroenterology position statement on serrated polyps in the colon and rectum. Gut. 2017;66:1181–96.CrossRefPubMed
41.
Zurück zum Zitat Rex DK, Ahnen DJ, Baron JA, Batts KP, Burke CA, Burt RW, et al. Serrated lesions of the colorectum: review and recommendations from an expert panel. Am J Gastroenterol. 2012;107:1315–29 (quiz 1314, 1330).CrossRefPubMedPubMedCentral Rex DK, Ahnen DJ, Baron JA, Batts KP, Burke CA, Burt RW, et al. Serrated lesions of the colorectum: review and recommendations from an expert panel. Am J Gastroenterol. 2012;107:1315–29 (quiz 1314, 1330).CrossRefPubMedPubMedCentral
43.
Zurück zum Zitat Zorzi M, Senore C, Da Re F, Barca A, Bonelli LA, Cannizzaro R, et al. Detection rate and predictive factors of sessile serrated polyps in an organised colorectal cancer screening programme with immunochemical faecal occult blood test: the EQuIPE study (Evaluating Quality Indicators of the Performance of Endoscopy). Gut. 2017;66:1233–40.CrossRefPubMed Zorzi M, Senore C, Da Re F, Barca A, Bonelli LA, Cannizzaro R, et al. Detection rate and predictive factors of sessile serrated polyps in an organised colorectal cancer screening programme with immunochemical faecal occult blood test: the EQuIPE study (Evaluating Quality Indicators of the Performance of Endoscopy). Gut. 2017;66:1233–40.CrossRefPubMed
44.
Zurück zum Zitat Chang L-C, Shun C-T, Hsu W-F, Tu C-H, Tsai P-Y, Lin B-R, et al. Fecal immunochemical test detects sessile serrated adenomas and polyps with a low level of sensitivity. Clin Gastroenterol Hepatol. 2017;15(872–9):e1. Chang L-C, Shun C-T, Hsu W-F, Tu C-H, Tsai P-Y, Lin B-R, et al. Fecal immunochemical test detects sessile serrated adenomas and polyps with a low level of sensitivity. Clin Gastroenterol Hepatol. 2017;15(872–9):e1.
45.
Zurück zum Zitat Heigh RI, Yab TC, Taylor WR, Hussain FTN, Smyrk TC, Mahoney DW, et al. Detection of colorectal serrated polyps by stool DNA testing: comparison with fecal immunochemical testing for occult blood (FIT). PLoS ONE. 2014;9:e85659.CrossRefPubMedPubMedCentral Heigh RI, Yab TC, Taylor WR, Hussain FTN, Smyrk TC, Mahoney DW, et al. Detection of colorectal serrated polyps by stool DNA testing: comparison with fecal immunochemical testing for occult blood (FIT). PLoS ONE. 2014;9:e85659.CrossRefPubMedPubMedCentral
46.
Zurück zum Zitat Wieten E, Schreuders EH, Grobbee EJ, Nieboer D, Bramer WM, Lansdorp-Vogelaar I, et al. Incidence of faecal occult blood test interval cancers in population-based colorectal cancer screening: a systematic review and meta-analysis. Gut. 2018. https://doi.org/10.1136/gutjnl-2017-315340. Wieten E, Schreuders EH, Grobbee EJ, Nieboer D, Bramer WM, Lansdorp-Vogelaar I, et al. Incidence of faecal occult blood test interval cancers in population-based colorectal cancer screening: a systematic review and meta-analysis. Gut. 2018. https://​doi.​org/​10.​1136/​gutjnl-2017-315340.
Metadaten
Titel
Contribution of the OC Sensor® immunoassay in comparison to the Hemoccult II® guaiac-test in organized colorectal cancer screening
verfasst von
Carole Vitellius
Margot Laly
Anne-Sophie Banaszuk
Isabelle Deherce
Nathanaëlle Cornet
Sandrine Bertrais
Patrick Saulnier
François-Xavier Caroli-Bosc
Publikationsdatum
08.12.2018
Verlag
Springer Netherlands
Erschienen in
European Journal of Epidemiology / Ausgabe 2/2019
Print ISSN: 0393-2990
Elektronische ISSN: 1573-7284
DOI
https://doi.org/10.1007/s10654-018-0471-z

Weitere Artikel der Ausgabe 2/2019

European Journal of Epidemiology 2/2019 Zur Ausgabe

PERINATAL EPIDEMIOLOGY

Apgar score and risk of autism